Abstract
Parkinson’s disease (PD) is a common neurodegenerative disorder that primarily afflicts the elderly. It is characterized by motor dysfunction due to extensive neuron loss in the substantia nigra pars compacta. There are multiple biological processes that are negatively impacted during the pathogenesis of PD, and are implicated in the cell death in this region. Neuroinflammation is evidently involved in PD pathology and mitigating the inflammatory cascade has been a therapeutic strategy. Age is the number one risk factor for PD and thus needs to be considered in the context of disease pathology. Here, we discuss the role of neuroinflammation within the context of aging as it applies to the development of PD, and the potential for two representative compounds, fractalkine and astaxanthin, to attenuate the pathophysiology that modulates neurodegeneration that occurs in Parkinson’s disease.
Document Type
Review
Publication Date
9-23-2016
Digital Object Identifier (DOI)
https://doi.org/10.3390/brainsci6040041
Funding Information
This work was supported by NIA grants AG04418 (PCB), AG044919 (PCB); VA IO1BX000231 (PCB), and the Michael J Fox foundation (KN/PCB). This work was supported by the federal government.
Repository Citation
Grimmig, Bethany; Morganti, Josh; Nash, Kevin; and Bickford, Paula C., "Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease" (2016). Sanders-Brown Center on Aging Faculty Publications. 69.
https://uknowledge.uky.edu/sbcoa_facpub/69
Included in
Epidemiology Commons, Family, Life Course, and Society Commons, Geriatrics Commons, Neurosciences Commons
Notes/Citation Information
Published in Brain Sciences, v. 6, issue 4, 41, p. 1-12.
© 2016 by the authors; licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).